New stem cell method aims to cut transplant risks for blood cancer patients
NCT ID NCT02323867
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-versus-host disease, a serious complication. About 140 participants will receive this treatment to see if it improves survival and reduces side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19103, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stem cell transplant with T cell and B cell depletion
What this could lead to
If successful, this could offer a safer way to use donor stem cells for patients with blood cancers, potentially reducing severe side effects and improving survival.
What could go wrong
This is a Phase 2 study with 140 participants, so results are still early. The procedure carries risks like infection, graft failure, or graft-versus-host disease, and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.